Sirnaomics, Inc. is a biopharmaceutical company discovering and developing novel targeted therapeutics for critical human diseases by using RNA interference (RNAi) technology. The company was founded in early 2007 with the mission of advancing RNAi technology using multi-targeted design of small interfering RNA (siRNA) and nanoparticle-enhanced delivery. The name of the company Sirnaomics (/ser-'now-miks/) is derived from the molecular terminology "siRNA" with the suffix "-omics" to signify the bridge between the study of the structure and function of small interfering RNAs (including their gene silencing properties) and the molecular comprehension of the complex interplay between genes these molecules target and pathways implicated in disease. Read more...
RNA Interference (RNAi) has emerged as a breakthrough in the life sciences industry. It presents extensive potential in multiple areas, such as drug discovery, drug development, and therapeutic applications for various indications along with aiding in the basic research. It has been found that, various components, such as siRNA & miRNA possess immense opportunities and provides a wide range in different drug classes. Besides, these molecules find wide applications in various sectors, such as functional genomics, disease diagnostics, and agriculture, among others. Many studies indicate that the usage of siRNA and miRNA in industries and academic institutions will witness ... Read more
STP702 (FluQuit) -
siRNA Therapeutics against Influenza Infection
Our patented siRNA therapeutics shown to have efficacy against H5N1 (avian flu) have also demonstrated inhibitory activity against H1N1 (swine flu). With the recent pandemic of H1N1 the market for vaccines and therapeutics has increased dramatically in to $billions. With the rapid mutation rate of the flu virus we are seeing resistance to drugs such as amantadine and even tamiflu. Sirnaomics has licensed IP describing siRNA sequences for use in a therapeutic cocktail against flu and has identified a vehicle for administration of these siRNAs to the lung.